QVT Financial LP Sells 3,462 Shares of argenex SE $ARGX

QVT Financial LP trimmed its stake in argenex SE (NASDAQ:ARGX) by 39.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,218 shares of the company’s stock after selling 3,462 shares during the period. argenex accounts for 0.4% of QVT Financial LP’s portfolio, making the stock its 24th largest position. QVT Financial LP’s holdings in argenex were worth $4,388,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the stock. Sands Capital Management LLC raised its position in shares of argenex by 2,046.6% in the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock worth $300,110,000 after acquiring an additional 340,245 shares in the last quarter. Mariner LLC raised its position in shares of argenex by 11.0% in the 4th quarter. Mariner LLC now owns 3,754 shares of the company’s stock worth $3,156,000 after acquiring an additional 371 shares in the last quarter. Focus Partners Wealth raised its position in shares of argenex by 631.3% in the 4th quarter. Focus Partners Wealth now owns 3,481 shares of the company’s stock worth $2,927,000 after acquiring an additional 3,005 shares in the last quarter. Kennedy Capital Management LLC raised its position in shares of argenex by 1.5% in the 4th quarter. Kennedy Capital Management LLC now owns 3,545 shares of the company’s stock worth $2,981,000 after acquiring an additional 52 shares in the last quarter. Finally, Arax Advisory Partners raised its position in shares of argenex by 134.8% in the 4th quarter. Arax Advisory Partners now owns 155 shares of the company’s stock worth $130,000 after acquiring an additional 89 shares in the last quarter. 60.32% of the stock is owned by institutional investors.

argenex Price Performance

Shares of ARGX stock opened at $893.52 on Monday. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The stock’s fifty day moving average price is $812.09 and its 200 day moving average price is $811.50. The company has a market cap of $55.57 billion, a price-to-earnings ratio of 39.78, a price-to-earnings-growth ratio of 1.37 and a beta of 0.47.

argenex (NASDAQ:ARGX) last announced its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The firm had revenue of $1.31 billion for the quarter. As a group, equities research analysts anticipate that argenex SE will post 26.19 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on ARGX. Guggenheim boosted their price target on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Royal Bank Of Canada reduced their price target on argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a research report on Friday, February 27th. Wedbush reissued an “outperform” rating and issued a $1,000.00 price target on shares of argenex in a research report on Thursday. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Finally, HC Wainwright boosted their price target on argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,019.50.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.